Related Experiment Video
Updated: Sep 12, 2025
08:32
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
10.4K
Repurposing the hypoglycaemic agents for neuroinflammation, a comprehensive review.
Vandana Blossom1, Sheetal D Ullal2, Rajalakshmi Rai1
1Department of Anatomy, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, India.
3 Biotech
|August 7, 2025
Summary
Repurposing antidiabetic drugs like glibenclamide and liraglutide shows promise for treating neuroinflammation by targeting shared pathways such as the NLRP3 inflammasome. These medications offer potential therapeutic benefits for neurological disorders and diabetes.
Area of Science:
- Neuroscience
- Immunology
- Endocrinology
Background:
- Shared pathways link neuroinflammation and diabetes mellitus, involving the NLRP3 inflammasome and IL-1β production.
- Chronic hyperactivation of the hypothalamo-pituitary-adrenal axis and innate immunity contribute to neurological disorders and diabetes.
- Drug repurposing offers a faster clinical translation for neuroinflammation treatments compared to novel drug development.
Purpose of the Study:
- To explore the potential of repurposed antidiabetic medications in treating neuroinflammation.
- To identify specific antidiabetic drugs and their mechanisms of action relevant to neuroinflammatory pathways.
- To highlight the significance of metabolic health in neurodegenerative diseases.
Main Methods:
- Review of existing literature on antidiabetic medications and their effects on neuroinflammation.
- Analysis of drug mechanisms, including inhibition of NLRP3 inflammasome and modulation of signaling pathways (e.g., ERK/STAT3/NF-κB).
- Examination of clinical and preclinical data on drugs like glibenclamide, liraglutide, empagliflozin, and insulin.
Main Results:
- Glibenclamide inhibits the NLRP3 inflammasome, suggesting utility in neuroinflammatory disorders.
- Liraglutide demonstrates benefits in glycaemic control and reducing neuroinflammation markers, particularly in obese patients.
- Sulfonylureas and empagliflozin show potential in decreasing neuroinflammation and offering neuroprotection, respectively.
- Repurposed antidiabetic drugs like metformin, thiazolidinediones, and insulin are viable candidates for neuroinflammation treatment.
Conclusions:
- The interplay between diabetes and neuroinflammation underscores the importance of metabolic health in neurodegenerative diseases.
- Targeting shared pathways offers a strategy for simultaneous prevention and treatment of both conditions.
- Drug repurposing of antidiabetic medications presents a promising avenue for managing neuroinflammatory disorders.
More Related Videos
Related Concept Videos
01:15Hypoglycemia and Glucagon
337
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
337
01:06Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
01:24Glucagon-like Receptor Agonists
419
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
419
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
298
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
298